Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 12 studies | 25% ± 9% | |
glutamatergic neuron | 11 studies | 40% ± 22% | |
GABAergic neuron | 9 studies | 40% ± 21% | |
oligodendrocyte | 7 studies | 26% ± 10% | |
oligodendrocyte precursor cell | 7 studies | 27% ± 12% | |
neuron | 6 studies | 31% ± 9% | |
amacrine cell | 6 studies | 24% ± 5% | |
interneuron | 6 studies | 43% ± 25% | |
microglial cell | 6 studies | 22% ± 6% | |
epithelial cell | 6 studies | 25% ± 7% | |
astrocyte | 6 studies | 31% ± 12% | |
retina horizontal cell | 5 studies | 28% ± 7% | |
fibroblast | 5 studies | 18% ± 2% | |
macrophage | 5 studies | 24% ± 5% | |
granule cell | 4 studies | 21% ± 5% | |
retinal ganglion cell | 4 studies | 42% ± 19% | |
myeloid cell | 4 studies | 21% ± 4% | |
adipocyte | 4 studies | 28% ± 16% | |
GABAergic interneuron | 3 studies | 28% ± 2% | |
rod bipolar cell | 3 studies | 21% ± 1% | |
hepatocyte | 3 studies | 39% ± 14% | |
alveolar macrophage | 3 studies | 23% ± 7% | |
cardiac muscle cell | 3 studies | 19% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2340.36 | 1444 / 1445 | 100% | 19.95 | 183 / 183 |
brain | 100% | 3564.14 | 2638 / 2642 | 100% | 28.17 | 705 / 705 |
prostate | 100% | 2284.02 | 244 / 245 | 100% | 18.49 | 501 / 502 |
thymus | 100% | 2947.32 | 653 / 653 | 99% | 27.07 | 601 / 605 |
lung | 99% | 2112.91 | 574 / 578 | 100% | 15.96 | 1155 / 1155 |
breast | 100% | 2284.80 | 459 / 459 | 99% | 20.36 | 1109 / 1118 |
ovary | 100% | 2563.19 | 180 / 180 | 99% | 14.28 | 426 / 430 |
bladder | 100% | 2933.95 | 21 / 21 | 99% | 14.90 | 497 / 504 |
kidney | 100% | 1798.52 | 89 / 89 | 99% | 20.30 | 888 / 901 |
uterus | 100% | 3194.12 | 170 / 170 | 97% | 15.12 | 447 / 459 |
intestine | 100% | 3086.19 | 966 / 966 | 96% | 11.71 | 505 / 527 |
stomach | 99% | 1671.57 | 355 / 359 | 96% | 14.60 | 275 / 286 |
liver | 100% | 2268.06 | 225 / 226 | 95% | 11.97 | 387 / 406 |
skin | 100% | 2366.84 | 1804 / 1809 | 94% | 17.50 | 445 / 472 |
adrenal gland | 100% | 2841.13 | 258 / 258 | 94% | 12.92 | 216 / 230 |
pancreas | 89% | 857.44 | 293 / 328 | 98% | 14.14 | 175 / 178 |
adipose | 100% | 2599.56 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2717.89 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 11568.28 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1390.83 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 17.34 | 1 / 1 |
tonsil | 0% | 0 | 0 / 0 | 98% | 12.79 | 44 / 45 |
heart | 97% | 3046.16 | 834 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 79% | 7.38 | 23 / 29 |
eye | 0% | 0 | 0 / 0 | 74% | 7.80 | 59 / 80 |
peripheral blood | 67% | 783.34 | 621 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0032436 | Biological process | positive regulation of proteasomal ubiquitin-dependent protein catabolic process |
GO_0006515 | Biological process | protein quality control for misfolded or incompletely synthesized proteins |
GO_0031462 | Cellular component | Cul2-RING ubiquitin ligase complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005515 | Molecular function | protein binding |
Gene name | ZYG11B |
Protein name | ZYG11B (Zyg-11 family member B, cell cycle regulator) Protein zyg-11 homolog B |
Synonyms | KIAA1730 |
Description | FUNCTION: Serves as substrate adapter subunit in the E3 ubiquitin ligase complex ZYG11B-CUL2-Elongin BC. Acts to target substrates bearing N-terminal degrons for proteasomal degradation with the first four residues of substrates being the key recognition elements . Prefers Nt-Gly but also has the capacity to recognize Nt-Ser, -Ala and -Cys . Involved in the clearance of proteolytic fragments generated by caspase cleavage during apoptosis since N-terminal glycine degrons are strongly enriched at caspase cleavage sites. Also important in the quality control of protein N-myristoylation in which N-terminal glycine degrons are conditionally exposed after a failure of N-myristoylation . In addition, plays a role in the amplification of cGAS to enhance innate immune response. Mechanistically, strengthens the processes of cGAS binding with dsDNA and assembling oligomers and also accelerates and stabilizes cGAS-DNA condensation, thereby enhancing production of antiviral IFNs and inflammatory cytokines . . |
Accessions | ENST00000294353.7 [Q9C0D3-1] A8DPD7 ENST00000545132.5 Q9C0D3 |